<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361138</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3824-102</org_study_id>
    <nct_id>NCT02361138</nct_id>
  </id_info>
  <brief_title>The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers</brief_title>
  <official_title>Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Study Following Multiple Dose of SHR3824 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an
      insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple-dose
      study the investigators evaluated the safety, tolerability and PK/PD profiles of SHR3824 in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(Area under the curve) of SHR3824.</measure>
    <time_frame>day1 and day11 to day 13.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax(the maximum concentration) of SHR3824.</measure>
    <time_frame>day1 and day11 to day 13.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax(the time reaching maximum concentration) of SHR3824.</measure>
    <time_frame>day1 and day11 to day 13.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Halflife of SHR3824.</measure>
    <time_frame>day1 and day11 to day 13.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of SHR3824.</measure>
    <time_frame>day1 and day11 to day 13.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>V/F of SHR3824.</measure>
    <time_frame>day1 and day11 to day 13.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio of SHR3824</measure>
    <time_frame>Up to day 13.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine glucose concentration of SHR3824.</measure>
    <time_frame>day1 and day11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma glucose concentration of SHR3824.</measure>
    <time_frame>day1 and day11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events, vital signs, physical exams , ECG, clinical labs</measure>
    <time_frame>Days -14 to -1, 0, 13.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Days -14 to -1, 0, 2, 9, 13.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Cohort SHR3824/Placebo 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR3824 1.25 mg/day or placebo for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort SHR3824/Placebo 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR3824 2.5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort SHR3824/Placebo 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR3824 5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort SHR3824/Placebo 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR3824 10 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort SHR3824/Placebo 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR3824 25 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort SHR3824/Placebo 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR3824 100 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR3824</intervention_name>
    <arm_group_label>Cohort SHR3824/Placebo 1.25 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 2.5 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 5 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 10 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 25 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 100mg</arm_group_label>
    <other_name>Henagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort SHR3824/Placebo 1.25 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 2.5 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 5 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 10 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 25 mg</arm_group_label>
    <arm_group_label>Cohort SHR3824/Placebo 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Chinese male and female subjects aged 18 to 45 years.

          -  BMI:18 -25 kg/m2.

          -  Healthy according to medical history, physical examination findings, 12-lead ECG
             findings, and clinical laboratory evaluations.

        Exclusion criteria:

          -  History of or current clinically significant medical illness as determined by the
             Investigator.

          -  History of clinically significant allergies, especially known hypersensitivity or
             intolerance to lactose.

          -  Pregnancy or breastfeeding . Significant acute or chronic medical illness, including
             renal impairment, or recent surgery.

          -  Donation of blood or plasma within the 4 weeks prior to the start of the study or
             acceptance of blood transfusion within 8 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR3824 Type 2 diabetes mellitus SGLT2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

